Synbiotics Easing Renal Failure by Improving Gut Microbiology II (SYNERGY II): A Feasibility Randomized Controlled Trial

Synbiotics have emerged as a therapeutic strategy for modulating the gut microbiome and targeting novel cardiovascular risk factors, including uremic toxins indoxyl sulfate (IS) and p-cresyl sulfate (PCS). This study aims to evaluate the feasibility of a trial of long-term synbiotic supplementation...

Descripción completa

Detalles Bibliográficos
Autores principales: McFarlane, Catherine, Krishnasamy, Rathika, Stanton, Tony, Savill, Emma, Snelson, Matthew, Mihala, Gabor, Kelly, Jaimon T., Morrison, Mark, Johnson, David W., Campbell, Katrina L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708915/
https://www.ncbi.nlm.nih.gov/pubmed/34960037
http://dx.doi.org/10.3390/nu13124481

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708915/
https://www.ncbi.nlm.nih.gov/pubmed/34960037
http://dx.doi.org/10.3390/nu13124481

Ejemplares similares